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Abstract 
Randomized controlled trials (RCT) are the gold standard for evaluation of the efficacy and safety of 
investigational interventions. If every patient in an RCT were to adhere to the randomized treatment, one 
could simply analyze the complete data to infer the treatment effect. However, intercurrent events (ICEs) 
including the use of concomitant medication for unsatisfactory efficacy, treatment discontinuation due to 
adverse events, or lack of efficacy, may lead to interventions that deviate from the original treatment 
assignment. Therefore, defining the appropriate estimand (the appropriate parameter to be estimated) 
based on the primary objective of the study is critical prior to determining the statistical analysis method 
and analyzing the data. The International Council for Harmonisation (ICH) E9 (R1), published on 
November 20, 2019, provided 5 strategies to define the estimand: treatment policy, hypothetical, 
composite variable, while on treatment and principal stratum. In this article, we propose an estimand 
using a mix of strategies in handling ICEs. This estimand is an average of the “null” treatment difference 
for those with ICEs potentially related to safety and the treatment difference for the other patients if they 
would complete the assigned treatments. Two examples from clinical trials evaluating anti-diabetes 
treatments are provided to illustrate the estimation of this proposed estimand and to compare it with the 
estimates for estimands using hypothetical and treatment policy strategies in handling ICEs.  
Keywords: hybrid estimand, theoretic estimand, de facto estimand, missing data. 
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1. Introduction 
The first randomized controlled trials (RCTs) in medicine were conducted as early as 1948.1 
RCTs have remained the gold standard for evaluation of the efficacy and safety of investigational 
interventions (drugs, biologics, devices, and other treatments). Ideally, all patients who 
participate in RCTs can adhere to the assigned treatment and complete the studies, allowing for 
the analysis of complete data. Often, however, post-baseline factors prevent patients from 
completing the designed treatment. Such factors include unsatisfactory efficacy, adverse events 
(AEs), or other reasons not related to the efficacy and safety of the treatment. These events, 
called intercurrent events (ICEs), either result in non-compliance with the study intervention 
(e.g., reduced dose level or discontinuation of the intervention), and/or use of additional 
medications for unsatisfactory efficacy (often called rescue medication). Therefore, ICEs, which 
affect the existence of observations or observed values that do not objectively reflect the 
originally intended treatment, create ambiguity in the estimation of the treatment effect.  
The National Research Council (United States) Panel recommended that the estimand should be 
clearly defined before constructing the estimator.2 The International Council for Harmonisation 
(ICH) E9 (R1)3 further clarifies the process of defining an estimand by considering:  
• Treatment(s) of interest – the treatment condition of interest and, as appropriate, the 
alternative treatment condition to which comparison will be made 
• Handling of relevant ICEs with appropriate strategies. Five strategies are proposed: 
treatment policy, hypothetical, composite variable, while on treatment and principal 
stratum 
• Population of interest  
• Outcome variable (endpoint) at patient level  
• Population-level summary of treatment effect 
Although people generally define the estimand based on only one of these 5 strategies in 
handling ICEs, these strategies do not need to be mutually exclusive. Further discussions on 
choosing and defining the estimand and aligning the estimators with the estimands were recently 
published.4,5,6 These publications further clarify (1) the need to evaluate what data are to be 
included, and (2) the separation of the definition of the estimand and handling of missing values.  
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An estimand for which ICEs are addressed using the treatment policy strategy and characterizes 
the treatment effect regardless of ICEs is generally preferred by many regulatory agencies. We 
call this estimand the de facto estimand in this article. This estimand is plausible if the treatment 
of interest is the study medication plus patients’ choice of additional rescue medication and 
choice of taking or stopping the study medication. People who prefer this estimand generally 
argue it is the closest to the intent-to-treat (ITT) principle7 and/or it mimics the treatment 
regimen in clinical practice and answers the question for treatment effectiveness.8 ICH E9 (R1) 
has discussed the drawbacks of blindly following the ITT principle. In addition, the purpose of 
most randomized clinical trials is to assess the efficacy and safety of the desired treatment in a 
controlled setting that could be considerably different from real-world clinical practice (e.g., 
frequencies of visit schedules, allowed concomitant medications, etc.), so the assessment of the 
effectiveness in the real world may not be achievable regardless of how the estimand is defined. 
Another widely used estimand uses a hypothetical strategy to handle ICEs. This estimand is the 
treatment difference as if all patients had completed the assigned treatment without ICEs. We 
call this hypothetical strategy the typical hypothetical strategy. However, it may not be 
convincing to consider whether a patient would have the benefit of the treatment when this 
patient could not tolerate the treatment. Lipkovich et al9 propose another hypothetical strategy 
assuming patients with ICEs have the same response as if they had taken the control treatment.  
The composite strategy is commonly used to address ICEs by incorporating patients with ICEs as 
non-responders in the definition of the endpoint (i.e., treatment failure). This addresses some of 
the drawbacks of the hypothetical strategy; however, handling ICEs only using the composite 
strategy does not consider the reasons for ICEs and may not be clinically meaningful for some 
cases. For example, while it is reasonable to consider those with treatment discontinuation due to 
AEs as non-responders, it may not be clinically meaningful to assume that those with treatment 
discontinuation due to reasons unrelated to efficacy or safety are non-responders.  
The estimands for which ICEs are addressed using the principal stratum strategy are clinically 
important but generally difficult to estimate because the principal stratum cannot be observed in 
parallel-group studies.10-15 A principal stratum is generally a hypothetical population of interest 
defined by the potential outcomes of a post-randomization variable. For example, one may be 
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interested in the principal stratum that patients can adhere to both the experimental and control 
treatments, while only the adherence status for their assigned treatment can be observed.  
In our experience, up to now, the primary estimand in a clinical trial has been almost exclusively 
defined using a single strategy in handling ICEs, regardless of the nature of ICEs. ICH E9 (R1) 
does not require all ICEs be handled the same way, as it may not be plausible to handle the 
treatment discontinuation due to adverse events in the same way as use of rescue medication. 
Akacha et al16 propose tripartite estimands: the difference in the proportion of patients with 
treatment discontinuations due to AEs, the difference in the proportion of patients with treatment 
disconsolation due to lack of efficacy (LoE), and the treatment difference in the primary outcome 
for adherers. While the authors emphasize the importance to differentiate the reasons for 
treatment discontinuations and classify them into three categories: due to AE, due to LoE or due 
to administrative reasons, their interest in the treatment difference is for adherers (a principal 
stratum). 
In this article, we introduce an estimand with a mix of strategies in handling ICEs according to 
the nature of individual ICEs. Data from 2 clinical trials evaluating anti-diabetes treatments (one 
superiority study and one non-inferiority study) are analyzed to illustrate the estimation for this 
new estimand.  
2. Methods 
The purpose of most RCTs is to assess the efficacy and safety of an experimental treatment 
under the ideal situation (i.e., without non-compliance, without dropout, and without rescue 
medication). However, it is often not possible to achieve the ideal situation due to ICEs. 
Therefore, we consider two questions of interest to determine the efficacy of an intervention for 
the population of all randomized patients, depending on people’s viewpoints. First, what is the 
average efficacy in the ideal situation when all patients would take the study medication as 
randomized? This corresponds to the estimand using a hypothetical strategy to handle ICEs, i.e., 
using the potential outcome assuming patients would complete the assigned treatment regardless 
of ICEs. In the rest of this article, we call this estimand the theoretic estimand. Most past 
research on handling missing values actually intends to estimate this estimand. However, when 
an ICE occurs due to clinically insurmountable reasons, it may be argued that it is unreasonable 
to assume patients would have had good efficacy if they had completed the intervention. In other 
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words, the hypothetical efficacy for those patients who are not able to complete the desired 
treatment can never be realized, despite the best effort of patients and investigators. Therefore, 
the second question is, what is the average efficacy for all randomized patients if those patients 
who are unable to complete the intervention due to insurmountable reasons (such as death or 
AEs) are considered to have no (“null”) efficacy (i.e., the treatment effect under the null 
hypothesis)? We define a “hybrid” estimand , which uses a mix of hypothetical strategies 
according to the nature of ICEs (assuming the potential outcome is “null” [no effect] for those 
discontinued due to insurmountable reasons and as if patients complete the treatment for those 
with other intercurrent events). In the rest of this article, we call the estimand with this specific 
mix of strategies handling ICEs the hybrid estimand. 
We classify all the ICEs into 3 categories:  
• Category 1, including ICEs potentially related to safety 
• Category 2, including ICEs potentially due to LoE 
• Category 3, including ICEs due to administrative reasons 
We consider the study medication has a relatively acute effect. For example, the response to the 
treatment should be apparent within a few weeks of taking the medication and should diminish 
after a few weeks of stopping the medication. Let 𝑍 be the treatment indicator (𝑍 = 0 for the 
control treatment, and 𝑍 = 1 for the experimental treatment), 𝑌(𝑍) denote the potential outcome 
(a continuous variable) for treatment 𝑍, and 𝑆(𝑍) denote the potential indicator whether a patient 
experiences an ICE of Category 1 when treated with treatment Z. Given an estimand, assume the 
null and alternative hypotheses are 
𝐻0: 𝜇 = 𝛿   vs.   𝐻𝑎: 𝜇 < 𝛿, 
where 𝜇 is the treatment difference (estimand), and 𝛿 = 0 for superiority studies and 𝛿 is the 
non-inferiority margin (NIM) for non-inferiority studies. 
The hybrid estimand can be defined mathematically as 
𝜇ℎ = 𝐸{[𝑌(1)(1 − 𝑆(1)) + (𝑌(0) + 𝛿)𝑆(1)] − 𝑌(0)}                             
= 𝐸{[𝑌(1) − 𝑌(0)](1 − 𝑆(1)) + 𝛿 ⋅ 𝑆(1)}                                      
= 𝐸[𝑌(1) − 𝑌(0)|𝑆(1) = 0] ⋅ Pr(𝑆(1) = 0) + 𝛿 ⋅ Pr(𝑆(1) = 1)                     (1) 
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Note 𝜇ℎ ≠ {Pr(𝑆(1) = 0) ⋅ 𝐸[𝑌(1)] + Pr(𝑆(1) = 1) ⋅ (𝛿 + 𝐸[𝑌(0)])} − 𝐸[𝑌(0)]. An estimator 
for 𝜇ℎ can be constructed as  
?̂?ℎ =
1
𝑛1
∑[(1 − 𝑆1𝑗)?̂?1𝑗(1) + 𝑆1𝑗(?̂?1𝑗(0) + 𝛿)]
𝑛1
𝑗=1
− 
1
𝑛0
∑ ?̂?0𝑗(0)
𝑛0
𝑗=1
,                       (2) 
where 𝑆1𝑗 is the observed indicator for patient j with an ICE of Category 1 for the experimental 
treatment group, ?̂?𝑧𝑗(𝑧
∗) is the estimated response for patient j in treatment group 𝑍 = 𝑧 while 
treated with treatment 𝑍 = 𝑧∗. The estimation ?̂?1𝑗(0) requires the framework of the principal 
stratification.  
• For those patients with non-missing response in the absence of ICEs, the estimated value 
?̂?𝑧𝑗(𝑧) equals the observed value 𝑌𝑧𝑗.  
• For patients who make a choice regarding treatment that represents an ICE of Categories 
2 and 3 (i.e., due to LoE or due to administrative reasons), the responses after intercurrent 
events (if there are any) are treated as missing values and are imputed as if patients had 
completed the treatment. In this article, missing values as a result of Category 3 of ICEs 
were considered missing completely at random (MCAR) or missing at random (MAR); 
the missing data as a result of Category 2 of ICEs were considered MAR since the 
efficacy measurements were collected right before the ICEs. Alternative assumptions for 
missing values may also be considered, but we do not discuss them here. 
• For patients with insurmountable ICEs (i.e., Category 1 of ICEs), the response is 
considered to be “null” (no effect). Specifically, responses (if there are any) after the 
ICEs are considered missing. For superiority studies, the response for patients with 
insurmountable intercurrent events in both treatment groups is considered to be like the 
control treatment. Therefore, the response for both treatments can be imputed using the 
observed data for patients in the control treatment group using a reference-based 
imputation.8, 17-23 For non-inferiority studies, the NIM can be added (assuming smaller 
outcome means better efficacy) to the imputed response for patients in the experimental 
treatment group to make the treatment difference have a “null” effect.24 Note this type of 
reference-based imputation assumes the data used for imputation can define the principal 
stratum {𝑗: 𝑆𝑧𝑗(1) = 1}. For example, if only the baseline variables in the experimental 
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treatment arm are used for the imputations, we assume this stratum can be determined 
through a stochastic model only depending on baseline covariates but not on the post-
baseline outcomes. This type of assumption is required for all reference-based imputation 
methods, but surprisingly, it is rarely explicitly pointed out.   
3. Examples 
We compare the estimators for three estimands listed in Table 1 for the change in Hemoglobin 
A1C (HbA1c) from baseline to the primary time point using data from two clinical studies 
(AWARD-1 [ClinicalTrials.gov Identifier: NCT01064687] and IMAGINE-3 [ClinicalTrials.gov 
Identifier: NCT01454284]):  
• The estimator for the theoretic estimand is based on the mixed models with repeated 
measures (MMRM) analysis. The responses after intercurrent events were set to be 
missing before performing the analysis. The MMRM approach, which assumes MCAR or 
MAR, is widely used in analyzing data from clinical trials.  
• The estimator for the de facto estimand included all observed data, used the jump-to-
reference (J2R) approach22 to impute missing values in the experimental treatment 
arm(s), and then applied MMRM to analyze the data. For non-inferiority studies, a NIM 
was added to the J2R imputed values. 
• The estimator for the hybrid estimand treated the responses after ICEs as missing values, 
imputed missing values as a result of ICEs due to AEs using J2R, and then analyzed the 
data using MMRM. Similarly, for non-inferiority studies, a NIM was added to the J2R 
imputed values. In this analysis, the missing data due to other preventable ICEs were 
implicitly imputed with MMRM. 
Note the above 3 estimators cannot be directly compared because they estimate different 
estimands. We perform the 3 analyses to illustrate the potential difference between estimands, 
realizing that the estimates are just one realization of the estimands. In both studies, the reasons 
for treatment discontinuation were collected in the clinical trial. However, some categories were 
vague, such as “investigator’s decision”, “subject’s decision”, etc. We reviewed the reasons for 
discontinuation, efficacy data (HbA1c and fasting serum glucose) and adverse events, and 
classified the ICEs into the 3 categories discussed in Section 2. More details can be found in Qu 
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et al.15, 16 When there was more than one potential reason for ICEs, we classified the ICEs based 
on the priority order of Categories 1, 2 and 3. 
3.1. AWARD-1 Study 
AWARD-1 is a randomized, parallel-arm study comparing dulaglutide 0.75 and 1.5 mg with 
exenatide twice daily and placebo.25 There were 978 patients randomized to dulaglutide 0.75  
mg, dulaglutide 1.5 mg, exenatide, or placebo with a 2:2:2:1 ratio. In this analysis, we compared 
dulaglutide 0.75 and 1.5 mg with placebo for the change in HbA1c from baseline to 26 weeks to 
show dulaglutide is superior to placebo.  
Table 2 summarizes the proportion of patients with each category of ICEs. A considerably larger 
proportion of patients in the placebo arm had Category-2 ICEs compared to dulaglutide 
treatment arms.  
The numbers of patients in each of the 3 arms and the estimates based on the 3 methods are 
shown in Table 3. The de facto estimand is consistent with the current FDA’s request to ignore 
the use of rescue medication. The estimator for the de facto estimand provided the most 
conservative estimates for the treatment difference, while the estimators for the theoretic 
estimand and hybrid estimand provided similar estimates. The smaller estimated treatment effect 
for the the de facto estimand was primarily due to the higher reduction in the mean change in 
HbA1c for the placebo arm with the inclusion of the data collected after initiation of rescue 
medications. The estimated mean change in HbA1c from baseline to 26 weeks for the placebo 
arm was 0.64% when using the treatment policy strategy to handle ICEs and -0.41% when using 
the typical hypothetical strategy and the mix of hypothetical strategies.   
3.2. IMAGINE-3 Study 
IMAGINE-3 is a double blind, randomized study comparing 2 basal insulins. 26 There were 1,114 
patients randomized to insulin peglispro or insulin glargine with a 3:2 randomization ratio. The 
primary objective was to show insulin peglispro was non-inferior to insulin glargine in the 
HbA1c level at 52 weeks using a non-inferiority margin of 0.4%. In this article, we considered a 
more commonly used endpoint: the change in HbA1c from baseline to 52 weeks. Note in linear 
models with adjustment for baseline HbA1c, the estimate for the treatment difference in the 
change in HbA1c from baseline to 52 weeks is the same as for HbA1c at 52 weeks. We analyzed 
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the data as a non-inferiority study using a non-inferiority margin of 0.4% as specified in the 
original protocol.  
Table 4 summarizes the proportion of patients with each category of ICEs. A larger proportion of 
patients with Category-1 ICEs in the insulin peglispro group compared to insulin glargine group. 
Table 5 shows the estimated mean change from baseline for each treatment arm and the 
treatment difference. The estimated mean treatment differences for the change in HbA1c from 
baseline to 52 weeks were -0.22%, -0.13%, and -0.17% for the theoretic, de facto and hybrid 
estimands. The estimates for the mean change from baseline to 52 weeks for insulin glargine 
were similar, and the major differences came from the estimates for insulin peglispro. Again, the 
treatment policy strategy provided the most conservative estimate. This is probably because in 
the estimation of the de facto estimand all missing values were imputed with a conservative 
approach under the “null” scenario and the response (if available) after stopping the study 
medication using “standard of care” basal insulin (mostly insulin glargine) was used, which in 
both cases might underestimate the benefit of the experimental treatment.  
4. Summary and Discussions 
Estimands and handling missing data are important topics in analyzing clinical trial data. ICH E9 
(R1) provides guidance on the steps and principles to define the estimand. However, debate 
continues on the definition or selection of estimands, especially on which strategies to be used in 
handling ICEs. For example, different stakeholders (sponsors, regulatory agencies, payers and 
journal reviewers) may not agree on the strategy of handling ICEs. Each stakeholder may 
provide an example of the plausibility of their preferred strategy. For example, sponsors argue 
the hypothetical strategy should be used to handle the ICE of rescue medication use as the 
outcomes collected after the use of rescue medication may not reflect the treatment of interest. 
On the other hand, a regulatory agency may argue the hypothetical strategy is not plausible for 
handling ICE of AEs when assuming patients who cannot tolerate the treatment still have the full 
benefit of the treatment. To meet the requirement for different stakeholders, different estimands 
are often defined. For example, two estimands were used in PIONEER-2 Study: “the treatment 
policy” estimand (using the treatment policy strategy for all ICEs) and the “trial product” 
estimand (using the typical hypothetical strategy for all ICEs).27 
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In this article, we propose an estimand with a mix of strategies in handling ICEs, which defines 
the treatment difference as the average of the treatment difference for those who could adhere to 
the treatment and the “null” treatment difference (no effect) for those who could NOT adhere to 
the treatment. Those who could adhere to the treatment include patients who adhere to treatment 
or had ICEs potentially related to LoE or administrative reasons. Those who could NOT adhere 
to treatment include patients with ICEs potentially related to AEs. This estimand answers an 
important clinical question, “What is the average treatment effect when considering patients with 
ICEs due to AEs as receiving no benefit?” In the estimation of this new estimand, we 
recommend the data collected after ICEs should NOT be included in the analysis, and the 
responses for these patients should be treated as missing. In the examples, we imputed the 
missing values as a result of ICEs due to lack of efficacy or due to administrative reasons 
implicitly in a MMRM model under the assumption of MAR, and imputed missing values as a 
result of ICEs due to AEs using a reference-based imputation under the assumption of missing 
not at random (MNAR). Other assumptions of missingness may be used for the estimation for 
the estimand with a mix of strategies in handling ICEs, but we advocate the underlying reasons 
for the missing values should be taken into consideration in determining the mechanisms of 
missingness, as recommended in literature. 28, 29 Therefore, considering the nature of ICEs is not 
only important for defining the estimand, but also for making the appropriate assumption in 
imputing the resulting missing values.  
Jump-to-reference imputation imputes the potential outcome for patients with ICEs of AE 
assuming “similar” patients in the control arm can be identified for imputation (i.e., the 
identification of the principal stratum of patients with ICEs due to AE or consistently estimating 
the probability of belonging to the principal stratum in the control arm). The probability for a 
patient belonging to the principal stratum can be estimated if the potential ICE under one 
treatment is independent of the potential outcome under the other treatment (principal 
ignorability assumption) 30, or under weaker but more complex assumptions14. While estimating 
the potential outcome for a principal stratum may be generally challenging, there are two reasons 
that it is less of a concern in the two examples to which we applied it. First, the principal stratum 
variable (ICE due to AE) is generally considered to be independent of the primary outcome of 
HbA1c for the diabetes treatment. Second, the principal stratum size is relatively small 
(approximately 10-20% of the overall population). Note even for the estimand using the 
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treatment policy strategy to handle ICEs, a jump-to-reference imputation for missing values also 
requires the same “principal stratum” assumption, although most of time the assumption is not 
explicitly stated.  
We summarized 3 estimands in two clinical trials for evaluating anti-diabetes treatment: the 
theoretic estimand using the typical hypothetical strategy to handle all ICEs, the de facto 
estimand using the treatment policy strategy to handle all ICEs, and the hybrid estimand using a 
mix of hypothetical strategies in handling ICEs according to the nature of ICEs. In both 
examples, the estimates for the de facto estimand seemed to be the most conservative, and the 
estimates for the theoretic estimand based on the assumption of MAR provided the most liberal 
estimate for the treatment difference. The hybrid estimand, which has a clear and reasonable 
clinical meaning, addresses some criticisms for both theoretic and de facto estimands and can be 
a reasonable option for the primary estimand to evaluate treatment efficacy in clinical trials.  
We applied this framework for the primary objective, but it can certainly be applied to 
supplemental estimands and/or the sensitivity analysis for the primary/secondary objectives (with 
different assumptions for imputation). For example, with the same estimand, one can introduce a 
sensitivity parameter to impute the missing values due to ICEs related to AE.31,32 Note it is 
possible that one analysis could serve as the primary analysis for one estimand and a sensitivity 
analysis for another estimand.  
In the two examples, we used one type of hybrid strategies in handling ICEs. There are other 
possible mixes of strategies in defining estimands. For example, when the outcome is a binary 
variable (e.g., whether patients respond to the treatments), a composite strategy can be used to 
handle ICEs due to LoE and treat these patients as non-responders if the clinical interest is that 
patients who discontinued treatment due to LoE or use of rescue medication are considered not 
meeting the treatment objective. Note the hypothetical outcome for patients with ICEs related to 
AE may not have to be “null” effect. The “no benefit” potential outcome is no improvement in 
the outcome from baseline. If using this hypothetical strategy to handle ICEs, the potential 
outcome can be imputed using a return-to-baseline imputation.33 The “no benefit” potential 
outcome can also be considered to be the outcome assuming patients complete the study but 
there is no treatment from the occurrence of ICEs to the study end. If using this hypothetical 
strategy in handling ICEs, the outcomes for patients who have ICEs but complete the study may 
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be used in the analysis, and for patients who have ICEs and discontinue the study, the potential 
outcome can be imputed using patients with similar ICEs but with observed outcomes (retrieved 
dropout imputation).34 Each of the above hypothetical strategies requires certain assumptions. 
Some of above hypothetical strategies may be especially useful for non-inferiority studies in 
which different hypothetical strategies may be used to define “no benefit”. In this article, we use 
the “null hypothesis” hypothetical strategy to handle the ICEs related to AE, for which the 
estimand is equal to the treatment effect under the null hypothesis. 
To estimate the hybrid estimand, the key is accurate collection of the reasons for treatment 
discontinuation. This should not be an extra burden for data collection, as the exact reasons for 
treatment discontinuation should be an expectation in clinical trials even if we do not use the mix 
of strategies in handling ICEs. This may require more detailed information for the reasons for 
treatment discontinuation, and may allow for multiple categories of reasons (e.g., AE and LoE). 
In addition, we should classify the ICEs proactively before unblinding the treatment code to 
prevent potential bias. Finally, the proportion of patients with each category of ICEs may be 
compared between treatments to assess the objectivity of classification. For example, if 
Category-3 ICEs are not similar between treatments for double-blind studies, the classification 
may need further investigation.  
 
Acknowledgement 
We thank Drs. Ilya Lipkovich, Dawn Brooks and Angelyn Bethel for their scientific review of 
this manuscript and valuable comments, and Dr. Brad Woodward for useful suggestions. We 
would also like to thank the two anonymous referees for their valuable comments that helped 
significantly improve the presentation of this article.  
  
13 
 
References 
 
1.  Marshall G, Blacklock JWS, Cameron C, et al. Streptomycin treatment of pulmonary 
tuberculosis: a Medical Research Council investigation. BMJ 1948:2(4582):769-782. 
2.  National Research Council (US) Panel on Handling Missing Data in Clinical Trials. The 
prevention and treatment of missing data in clinical trials. Washington DC: National 
Academies Press; 2010.  
3.  European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis 
in clinical trials. 2019. https://database.ich.org/sites/default/files/E9-R1_Step 
4_Guideline_2019_1203.pdf [Accessed on March 14, 2020]. 
4. Ratitch B, Bell J, Mallinckrodt C, Bartlett JW, Goel N, Molenberghs G, O’Kelly M, Singh 
P, Lipkovich I. Choosing estimands in clinical trials: Putting the ICH E9 (R1) into practice. 
Ther Innov Regul Sci 2019:2168479019838827. doi: 10.1177/2168479019838827. 
5. Ratitch B, Goel N, Mallinckrodt C, Bell J, Bartlett JW, Molenberghs G, Singh P, Lipkovich 
I, O’Kelly M. Defining efficacy estimands in clinical trials: Examples illustrating ICH E9 
(R1) Guidelines. Ther Innov Regul Sci 2019:2168479019841316. doi: 
10.1177/2168479019841316. 
6. Mallinckrodt CH, Bell J, Liu G, Ratitch B, O’Kelly M, Lipkovich I, Singh P, Xu L, 
Molenberghs G. Aligning estimators with estimands in clinical trials: Putting the ICH E9 
(R1) Guidelines into practice. Ther Innov Regul Sci 2019:2168479019836979. doi: 
10.1177/2168479019836979. 
7. Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat 
in clinical trials. In: Peace KE, editor. Statistical issues in drug research and development. 
New York: Marcel Dekker; 1990. pp. 331-350. 
8. Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol 
deviation: a framework for relevant, accessible assumptions, and inference via multiple 
imputation. J Biopharm Stat 2013;23(6):1352-1371. 
9.    Lipkovich I, Ratitch B, Mallinckrodt C. Causal inference and estimands in clinical trials. 
Statistics in Biopharmaceutical Research. 2020, 12 (1): 54-67.  
10. Frangakis CE, Rubin DB. Principal stratification in causal inference. Biometrics 
2002;58(1):21-29. 
11. Permutt T. A taxonomy of estimands for regulatory clinical trials with discontinuations. Stat 
Med 2016;35(17):2865-2675. 
14 
 
12. Lou Y, Jones MP, Sun W. Estimation of causal effects in clinical endpoint bioequivalence 
studies in the presence of intercurrent events: noncompliance and missing data. J Biopharm 
Stat 2019;29(1):151-173. 
13.  Magnusson BP, Schmidli H, Rouyrre N, Scharfstein DO. Bayesian inference for a principal 
stratum estimand to assess the treatment effect in a subgroup characterized by post-
randomization events. arXiv 2018:1809.03741. 
14.  Qu Y, Fu H, Luo J, Ruberg SJ. A general framework for treatment effect estimators 
considering patient adherence. Statistics in Biopharmaceutical Research. 2020,12(1):1-8. 
15.  Qu Y, Luo J, Ruberg SJ.  Analysis using the tripartite estimand approach. 2020. Under 
journal review. https://arxiv.org/ftp/arxiv/papers/2005/2005.14624.pdf. 
16.  Akacha M, Bretz F, Ruberg S. Estimands in clinical trials - broadening the perspective. Stat 
Med 2017;36(1):5-19. 
17. Little R, Yau L. Intent-to-treat analysis for longitudinal studies with drop-outs. Biometrics 
1996;52(4):1324-1333. 
18. Carpenter JR, Kenward MG. Missing data in randomised controlled trials: a practical guide. 
2007. http://researchonline.lshtm.ac.uk/4018500/1/rm04 jh17 mk.pdf. [Accessed February 
21, 2019.] 
19. Ratitch, B., OKelly, M. Implementation of pattern-mixture models using standard 
SAS/STAT procedures. PharmaSUG, Paper-SP04. 
http://pharmasug.org/proceedings/2011/SP/PharmaSUG-2011-SP04.pdf. [Accessed 
February 21, 2019.] 
20. Mallinckrodt CH. Preventing and treating missing data in longitudinal clinical trials: a 
practical guide. Cambridge University Press; 2013 Jan 28. 
21. Teshome B, Lipkovich I, Molenberghs G, Mallinckrodt CH. Placebo multiple imputation: a 
new approach to sensitivity analyses for incomplete longitudinal clinical trial data. Journal 
of Biopharmaceutical Statistics. 2013. 
22. Carpenter JR, Roger JH, Kenward MG. Analysis of longitudinal trials with protocol 
deviation: a framework for relevant, accessible assumptions, and inference via multiple 
imputation. Journal of biopharmaceutical statistics. 2013 Nov 2;23(6):1352-71. 
23.  Mallinckrodt CH, Roger J, Chuang-Stein C, Molenberghs G, O'Kelly M, Ratitch B, Janssens 
M, Bunouf P. Recent developments in the prevention and treatment of missing data. Ther 
Innov Regul Sci 2014;48(1):68-80 
15 
 
24. Koch GG. Comments on ‘Current issues in non-inferiority trials’ by Thomas R. Fleming, 
Statistics in Medicine, DOI: 10.1002/sim.2855. Stat Med 2008;27:333–342. 
25.  Wysham C, Blevins T, Arakaki R, Colon G, Garcia P, Atisso C, Kuhstoss D, Lakshmanan 
M. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus 
exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes Care 
2014;37:2159-2167. 
26.  Bergenstal RM, Lunt H, Franek E, Travert F, Mou J, Qu Y, Antalis CJ, Hartman ML, 
Rosilio M, Jacober SJ, Bastyr EJ 3rd; IMAGINE 3 Trial Investigators. Randomized, double‐
blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination 
with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes 
Metab 2016;18:1081-1088. 
27.  Rodbard HW, Rosenstock J, Canani LH, Deerochanawong C, Gumprecht J, Lindberg SØ, 
Lingvay I, Søndergaard AL, Treppendahl MB, Montanya E. Oral semaglutide versus 
empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 
trial. Diabetes Care. 2019 Dec 1;42(12):2272-81. 
28.  National Research Council. The prevention and treatment of missing data in clinical trials. 
National Academies Press; 2010 Dec 21. 
29.  Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Frangakis C, 
Hogan JW, Molenberghs G, Murphy SA, Neaton JD. The prevention and treatment of 
missing data in clinical trials. New England Journal of Medicine. 2012 Oct 4;367(14):1355-
60. 
30.  Hayden D, Pauler DK, Schoenfeld D. An estimator for treatment comparisons among  
survivors in randomized trials. Biometrics. 2005;61(1):305–310. 
31.  Mehrotra DV, Liu F, Permutt T. Missing data in clinical trials: control-based mean 
imputation and sensitivity analysis. Pharmaceutical statistics. 2017 Sep;16(5):378-92. 
32.  Cro S, Morris TP, Kenward MG, Carpenter JR. Sensitivity analysis for clinical trials with 
missing continuous outcome data using controlled multiple imputation: A practical guide. 
Statistics in Medicine. 2020 May 17. 
33.  Zhang Y, Golm G, Liu G. A Likelihood-Based Approach for the Analysis of Longitudinal 
Clinical Trials with Return-to-Baseline Imputation. Statistics in Biosciences. 2020 
Apr;12(1):23-36. 
34.  Committee for Medicinal Products for Human Use (CHMP). “Guideline on Missing Data in 
Confirmatory Clinical Trials,” European Medicines Agency Committee for Medicinal 
Products for Human Use (CHMP), 2010. EMA/CPMP/EWP/1776/99 Rev. 1. [online], 
16 
 
Available at https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-
missing-data-confirmatory-clinical-trials_en.pdf. 
  
17 
 
Table 1. Three estimators for certain combinations of estimands, analysis datasets, and methods of handling missing 
values.  
Estimand Analysis Dataset Estimator and Handling Missing Values 
The theoretic estimand 
All data on treatment before 
ICEs 
MMRM based on MAR assumption 
The de facto estimand 
All available data, regardless 
of ICEs 
J2R MI for all missing values (MNAR); for non-
inferiority studies, the NIM is added to the imputed 
values 
MMRM on complete data 
The hybrid estimand 
All data on treatment before 
ICEs 
J2R MI for missing values for patients with Category 1 
ICEs (MNAR); for non-inferiority studies, the NIM is 
added to the imputed values 
MMRM including imputed data and assuming MAR for 
other missing data 
AE, adverse event; J2R, jump-to-reference; MAR, missing at random; MI, mixed imputation; MMRM, mixed 
models with repeated measures; NIM, non-inferiority margin; ICE, intercurrent events. 
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Table 2. Summary of ICEs in the AWARD-1 study (first 26 weeks) 
ICE Category* 
Placebo 
(N=141) 
Dulaglutide 0.75 mg 
(N=280) 
Dulaglutide 1.5 mg 
(N=279) 
Patients with ICEs 36 (25.5%) 33 (11.8%) 27 (9.7%) 
        Category 1 9 (6.4%) 18 (6.4%) 15 (5.4%) 
        Category 2 23 (16.3%) 10 (3.6%) 4 (1.4%) 
        Category 3 4 (2.8%) 5 (1.8%) 8 (2.9%) 
*Category 1 includes TDC due to AE, and TDC due to other reasons but with at least one persistent AE reported 
before DC; Category 2 includes TDC due to LoE, use of rescue med, and TDC due to other reasons with no 
persistent AEs reported before TDC and with deteriorated efficacy prior to TDC; Category 3 includes all other ICEs. 
Abbreviations: AE, adverse events; ICE, intercurrent events; LoE, lack of efficacy; TDC, treatment discontinuation. 
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Table 3. Estimated mean change in HbA1c from baseline to 26 weeks and treatment differences compared to 
placebo for the AWARD-1 study 
Method 
Placebo 
(N=141) 
 
Mean (SE) 
Dulaglutide 
0.75 mg 
(N=280) 
Mean (SE) 
Dulaglutide 
1.5 mg 
(N=279) 
Mean (SE) 
Dulaglutide 0.75 mg 
vs. Placebo 
 
Mean (95% CI) 
Dulaglutide 1.5 mg 
vs. Placebo 
 
Mean (95% CI) 
(A) MMRM for the 
theoretic estimand  
-0.41 (0.07) -1.26 (0.05) -1.51 (0.05) -0.85 (-1.02, -0.68) -1.10 (-1.27, 0.93) 
(B) Placebo-based 
imputation for the de 
facto estimand 
-0.64 (0.07) -1.29 (0.05) -1.52 (0.05) -0.65 (-0.82, -0.48) -0.88 (-1.05, -0.71) 
(C) Mixed 
imputation for the 
hybrid estimand 
-0.41 (0.07) -1.25 (0.05) -1.51 (0.05) -0.84 (-1.01, -0.67) -1.10 (-1.27, -0.93) 
Abbreviations: CI, confidence interval; HbA1c, Hemoglobin A1c; MMRM, mixed models with repeated measures; 
SE, standard error. 
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Table 4. Summary of ICEs in the IMAGINE-3 study 
ICE Category* Insulin Glargine 
(N=449) 
Insulin Peglispro 
(N=663) 
Patients with ICEs 81 (18.0%) 154 (23.2%) 
        Category 1  24 (5.3%) 70 (10.6%) 
        Category 2  8 (1.8%) 15 (2.3%) 
        Category 3  49 (10.9%) 69 (10.4%) 
*Category 1 includes TDC due to AE, and TDC due to other reasons but with at least one persistent AE reported 
before DC; Category 2 includes TDC due to LoE, use of rescue med, and TDC due to other reasons with no 
persistent AEs reported before TDC and with deteriorated efficacy prior to TDC; Category 3 includes all other ICEs. 
Abbreviations: AE, adverse events; ICE, intercurrent events; LoE, lack of efficacy; TDC, treatment discontinuation.  
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Table 5. Estimated mean change in HbA1c from baseline to 52 weeks and treatment differences for the IMAGINE-3 
study 
Method 
Insulin Glargine 
(N=444) 
 
Mean (SE) 
Insulin Peglispro 
(N=648) 
 
Mean (SE) 
Insulin Peglispro vs. Insulin 
Glargine 
 
Mean (95% CI) 
(A) MMRM for the theoretic 
estimand  
-0.24 (0.04) -0.46 (0.03) -0.22 (-0.32, -0.12) 
(B) Placebo-based imputation 
for the de facto estimand 
-0.26 (0.04) -0.38 (0.03) -0.13 (-0.22, -0.03) 
(C)  Mixed imputation  for the 
hybrid estimand 
-0.24 (0.04) -0.41 (0.03) -0.17 (-0.27, -0.07) 
Abbreviations: CI, confidence interval; HbA1c, Hemoglobin A1C; MMRM, mixed models with repeated measures; 
SE, standard error. 
 
 
